nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—CCR1—multiple sclerosis	0.81	1	CbGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL13—multiple sclerosis	0.00306	0.0489	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL3—multiple sclerosis	0.00218	0.0349	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCR3—multiple sclerosis	0.00203	0.0324	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR2—multiple sclerosis	0.00197	0.0315	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL10—multiple sclerosis	0.00164	0.0262	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CXCR3—multiple sclerosis	0.00162	0.0259	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCR2—multiple sclerosis	0.00158	0.0252	CbGpPWpGaD
Raltegravir—CCR1—medulla oblongata—multiple sclerosis	0.0015	0.206	CbGeAlD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL5—multiple sclerosis	0.00141	0.0225	CbGpPWpGaD
Raltegravir—CCR1—midbrain—multiple sclerosis	0.00137	0.188	CbGeAlD
Raltegravir—CCR1—spinal cord—multiple sclerosis	0.00134	0.184	CbGeAlD
Raltegravir—CCR1—G alpha (i) signalling events—S1PR1—multiple sclerosis	0.00132	0.0211	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR5—multiple sclerosis	0.00127	0.0203	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—BCHE—multiple sclerosis	0.00121	0.0194	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL13—multiple sclerosis	0.00115	0.0184	CbGpPWpGaD
Raltegravir—CCR1—nervous system—multiple sclerosis	0.00113	0.155	CbGeAlD
Raltegravir—CCR1—G alpha (i) signalling events—RGS1—multiple sclerosis	0.00112	0.0179	CbGpPWpGaD
Raltegravir—CCR1—central nervous system—multiple sclerosis	0.00109	0.149	CbGeAlD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.00105	0.0167	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCR5—multiple sclerosis	0.00102	0.0163	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000986	0.0158	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCL2—multiple sclerosis	0.000972	0.0155	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL13—multiple sclerosis	0.000972	0.0155	CbGpPWpGaD
Raltegravir—CCR1—brain—multiple sclerosis	0.000864	0.118	CbGeAlD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000845	0.0135	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.000821	0.0131	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—S1PR1—multiple sclerosis	0.000798	0.0128	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.000772	0.0123	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.000763	0.0122	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000747	0.0119	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.000742	0.0119	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.000644	0.0103	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GPR65—multiple sclerosis	0.000643	0.0103	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR2—multiple sclerosis	0.000626	0.01	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000618	0.00988	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.000617	0.00986	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000597	0.00955	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL13—multiple sclerosis	0.000588	0.0094	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000581	0.00929	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CNR1—multiple sclerosis	0.000578	0.00923	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00055	0.0088	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000536	0.00857	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.000531	0.00848	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00053	0.00847	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00052	0.00831	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000512	0.00818	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000498	0.00796	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000478	0.00764	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000469	0.00749	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000459	0.00734	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000451	0.00721	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCL5—multiple sclerosis	0.000448	0.00716	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL3—multiple sclerosis	0.000419	0.0067	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000414	0.00661	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000409	0.00654	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000403	0.00645	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CCR5—multiple sclerosis	0.000403	0.00645	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCR3—multiple sclerosis	0.00039	0.00623	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000383	0.00613	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR2—multiple sclerosis	0.000379	0.00606	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.000375	0.00599	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000375	0.00599	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000374	0.00598	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000374	0.00597	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00037	0.00591	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00037	0.00591	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000366	0.00584	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000363	0.00581	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000356	0.00569	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CNR1—multiple sclerosis	0.00035	0.00559	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RGS1—multiple sclerosis	0.000348	0.00556	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000332	0.00531	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GPR65—multiple sclerosis	0.00033	0.00528	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000321	0.00513	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LINGO1—multiple sclerosis	0.000319	0.0051	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—POMC—multiple sclerosis	0.000315	0.00504	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000315	0.00503	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000302	0.00482	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000277	0.00442	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL5—multiple sclerosis	0.000271	0.00433	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000251	0.00401	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000245	0.00392	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCR5—multiple sclerosis	0.000244	0.0039	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—S1PR1—multiple sclerosis	0.000242	0.00387	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GPC5—multiple sclerosis	0.000235	0.00376	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000228	0.00364	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.00022	0.00352	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL3—multiple sclerosis	0.000215	0.00344	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000214	0.00342	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000207	0.00331	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RGS1—multiple sclerosis	0.000206	0.00329	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.000202	0.00322	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR3—multiple sclerosis	0.0002	0.0032	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000198	0.00316	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GPR65—multiple sclerosis	0.000195	0.00312	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR2—multiple sclerosis	0.000195	0.00311	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—POMC—multiple sclerosis	0.000191	0.00305	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL2—multiple sclerosis	0.000187	0.00299	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.00018	0.00287	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CNR1—multiple sclerosis	0.00018	0.00287	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000179	0.00286	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL13—multiple sclerosis	0.000178	0.00285	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000178	0.00284	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000162	0.00258	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000153	0.00245	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.00014	0.00223	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL5—multiple sclerosis	0.000139	0.00222	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000138	0.00221	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000136	0.00217	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.00013	0.00209	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL3—multiple sclerosis	0.000127	0.00203	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCR5—multiple sclerosis	0.000125	0.002	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000124	0.00197	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTGER4—multiple sclerosis	0.000122	0.00195	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PGR—multiple sclerosis	0.00012	0.00193	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR3—multiple sclerosis	0.000118	0.00189	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD28—multiple sclerosis	0.000117	0.00187	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR2—multiple sclerosis	0.000115	0.00184	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—POMC—multiple sclerosis	0.000108	0.00172	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CNR1—multiple sclerosis	0.000106	0.00169	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—POMC—multiple sclerosis	9.8e-05	0.00157	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL2—multiple sclerosis	9.59e-05	0.00153	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL10—multiple sclerosis	9.55e-05	0.00153	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SRM—multiple sclerosis	9.1e-05	0.00146	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—TYK2—multiple sclerosis	8.7e-05	0.00139	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—POMC—multiple sclerosis	8.44e-05	0.00135	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD86—multiple sclerosis	8.35e-05	0.00133	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL5—multiple sclerosis	8.22e-05	0.00131	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—multiple sclerosis	7.98e-05	0.00127	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—multiple sclerosis	7.61e-05	0.00122	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR5—multiple sclerosis	7.4e-05	0.00118	CbGpPWpGaD
Raltegravir—Arthralgia—Methylprednisolone—multiple sclerosis	7.32e-05	0.000609	CcSEcCtD
Raltegravir—Myalgia—Methylprednisolone—multiple sclerosis	7.32e-05	0.000609	CcSEcCtD
Raltegravir—Eye disorder—Prednisone—multiple sclerosis	7.31e-05	0.000608	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL2RA—multiple sclerosis	7.3e-05	0.00117	CbGpPWpGaD
Raltegravir—Anxiety—Methylprednisolone—multiple sclerosis	7.29e-05	0.000607	CcSEcCtD
Raltegravir—Infestation—Methotrexate—multiple sclerosis	7.28e-05	0.000606	CcSEcCtD
Raltegravir—Infestation NOS—Methotrexate—multiple sclerosis	7.28e-05	0.000606	CcSEcCtD
Raltegravir—Rash—Azathioprine—multiple sclerosis	7.27e-05	0.000605	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	7.27e-05	0.000605	CcSEcCtD
Raltegravir—Dermatitis—Azathioprine—multiple sclerosis	7.26e-05	0.000604	CcSEcCtD
Raltegravir—Depression—Methotrexate—multiple sclerosis	7.26e-05	0.000604	CcSEcCtD
Raltegravir—Ill-defined disorder—Dexamethasone—multiple sclerosis	7.25e-05	0.000604	CcSEcCtD
Raltegravir—Ill-defined disorder—Betamethasone—multiple sclerosis	7.25e-05	0.000604	CcSEcCtD
Raltegravir—Discomfort—Triamcinolone—multiple sclerosis	7.25e-05	0.000603	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—IL2—multiple sclerosis	7.24e-05	0.00116	CbGpPWpGaD
Raltegravir—Discomfort—Methylprednisolone—multiple sclerosis	7.23e-05	0.000602	CcSEcCtD
Raltegravir—Headache—Azathioprine—multiple sclerosis	7.22e-05	0.000601	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	7.22e-05	0.000601	CcSEcCtD
Raltegravir—Dry mouth—Triamcinolone—multiple sclerosis	7.17e-05	0.000597	CcSEcCtD
Raltegravir—Renal failure—Methotrexate—multiple sclerosis	7.16e-05	0.000596	CcSEcCtD
Raltegravir—Angiopathy—Prednisone—multiple sclerosis	7.1e-05	0.00059	CcSEcCtD
Raltegravir—Confusional state—Methylprednisolone—multiple sclerosis	7.07e-05	0.000589	CcSEcCtD
Raltegravir—Immune system disorder—Prednisone—multiple sclerosis	7.06e-05	0.000588	CcSEcCtD
Raltegravir—Malaise—Dexamethasone—multiple sclerosis	7.05e-05	0.000587	CcSEcCtD
Raltegravir—Malaise—Betamethasone—multiple sclerosis	7.05e-05	0.000587	CcSEcCtD
Raltegravir—Vertigo—Betamethasone—multiple sclerosis	7.02e-05	0.000584	CcSEcCtD
Raltegravir—Vertigo—Dexamethasone—multiple sclerosis	7.02e-05	0.000584	CcSEcCtD
Raltegravir—Infection—Triamcinolone—multiple sclerosis	6.99e-05	0.000581	CcSEcCtD
Raltegravir—Infection—Methylprednisolone—multiple sclerosis	6.97e-05	0.00058	CcSEcCtD
Raltegravir—Haematuria—Methotrexate—multiple sclerosis	6.94e-05	0.000578	CcSEcCtD
Raltegravir—Insomnia—Prednisolone—multiple sclerosis	6.92e-05	0.000575	CcSEcCtD
Raltegravir—Alopecia—Prednisone—multiple sclerosis	6.91e-05	0.000575	CcSEcCtD
Raltegravir—Hepatobiliary disease—Methotrexate—multiple sclerosis	6.89e-05	0.000573	CcSEcCtD
Raltegravir—Nervous system disorder—Methylprednisolone—multiple sclerosis	6.88e-05	0.000573	CcSEcCtD
Raltegravir—Epistaxis—Methotrexate—multiple sclerosis	6.87e-05	0.000571	CcSEcCtD
Raltegravir—Hypersensitivity—Mitoxantrone—multiple sclerosis	6.87e-05	0.000571	CcSEcCtD
Raltegravir—Paraesthesia—Prednisolone—multiple sclerosis	6.87e-05	0.000571	CcSEcCtD
Raltegravir—Mental disorder—Prednisone—multiple sclerosis	6.85e-05	0.00057	CcSEcCtD
Raltegravir—Nausea—Azathioprine—multiple sclerosis	6.85e-05	0.00057	CcSEcCtD
Raltegravir—Skin disorder—Methylprednisolone—multiple sclerosis	6.81e-05	0.000567	CcSEcCtD
Raltegravir—Malnutrition—Prednisone—multiple sclerosis	6.81e-05	0.000567	CcSEcCtD
Raltegravir—Erythema—Prednisone—multiple sclerosis	6.81e-05	0.000567	CcSEcCtD
Raltegravir—Hyperhidrosis—Triamcinolone—multiple sclerosis	6.8e-05	0.000566	CcSEcCtD
Raltegravir—Hyperhidrosis—Methylprednisolone—multiple sclerosis	6.78e-05	0.000564	CcSEcCtD
Raltegravir—Hypertension—Betamethasone—multiple sclerosis	6.75e-05	0.000562	CcSEcCtD
Raltegravir—Hypertension—Dexamethasone—multiple sclerosis	6.75e-05	0.000562	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APOE—multiple sclerosis	6.74e-05	0.00108	CbGpPWpGaD
Raltegravir—Asthenia—Mitoxantrone—multiple sclerosis	6.69e-05	0.000556	CcSEcCtD
Raltegravir—Myalgia—Betamethasone—multiple sclerosis	6.66e-05	0.000554	CcSEcCtD
Raltegravir—Myalgia—Dexamethasone—multiple sclerosis	6.66e-05	0.000554	CcSEcCtD
Raltegravir—Anxiety—Betamethasone—multiple sclerosis	6.63e-05	0.000552	CcSEcCtD
Raltegravir—Anxiety—Dexamethasone—multiple sclerosis	6.63e-05	0.000552	CcSEcCtD
Raltegravir—Discomfort—Dexamethasone—multiple sclerosis	6.58e-05	0.000547	CcSEcCtD
Raltegravir—Discomfort—Betamethasone—multiple sclerosis	6.58e-05	0.000547	CcSEcCtD
Raltegravir—Pain—Prednisolone—multiple sclerosis	6.54e-05	0.000544	CcSEcCtD
Raltegravir—Hepatitis—Methotrexate—multiple sclerosis	6.54e-05	0.000544	CcSEcCtD
Raltegravir—Urinary tract disorder—Methotrexate—multiple sclerosis	6.45e-05	0.000537	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYP27B1—multiple sclerosis	6.41e-05	0.00103	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP24A1—multiple sclerosis	6.41e-05	0.00103	CbGpPWpGaD
Raltegravir—Urethral disorder—Methotrexate—multiple sclerosis	6.41e-05	0.000533	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.41e-05	0.000533	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.39e-05	0.000532	CcSEcCtD
Raltegravir—Diarrhoea—Mitoxantrone—multiple sclerosis	6.38e-05	0.000531	CcSEcCtD
Raltegravir—Insomnia—Triamcinolone—multiple sclerosis	6.36e-05	0.000529	CcSEcCtD
Raltegravir—Insomnia—Methylprednisolone—multiple sclerosis	6.35e-05	0.000528	CcSEcCtD
Raltegravir—Infection—Betamethasone—multiple sclerosis	6.34e-05	0.000527	CcSEcCtD
Raltegravir—Infection—Dexamethasone—multiple sclerosis	6.34e-05	0.000527	CcSEcCtD
Raltegravir—Ill-defined disorder—Prednisone—multiple sclerosis	6.32e-05	0.000526	CcSEcCtD
Raltegravir—Paraesthesia—Triamcinolone—multiple sclerosis	6.31e-05	0.000525	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisolone—multiple sclerosis	6.3e-05	0.000524	CcSEcCtD
Raltegravir—Paraesthesia—Methylprednisolone—multiple sclerosis	6.3e-05	0.000524	CcSEcCtD
Raltegravir—Visual impairment—Methotrexate—multiple sclerosis	6.3e-05	0.000524	CcSEcCtD
Raltegravir—Anaemia—Prednisone—multiple sclerosis	6.29e-05	0.000524	CcSEcCtD
Raltegravir—Nervous system disorder—Dexamethasone—multiple sclerosis	6.26e-05	0.000521	CcSEcCtD
Raltegravir—Nervous system disorder—Betamethasone—multiple sclerosis	6.26e-05	0.000521	CcSEcCtD
Raltegravir—Agitation—Prednisone—multiple sclerosis	6.26e-05	0.000521	CcSEcCtD
Raltegravir—Thrombocytopenia—Betamethasone—multiple sclerosis	6.25e-05	0.00052	CcSEcCtD
Raltegravir—Thrombocytopenia—Dexamethasone—multiple sclerosis	6.25e-05	0.00052	CcSEcCtD
Raltegravir—Dyspepsia—Triamcinolone—multiple sclerosis	6.19e-05	0.000515	CcSEcCtD
Raltegravir—Erythema multiforme—Methotrexate—multiple sclerosis	6.18e-05	0.000514	CcSEcCtD
Raltegravir—Dyspepsia—Methylprednisolone—multiple sclerosis	6.18e-05	0.000514	CcSEcCtD
Raltegravir—Hyperhidrosis—Dexamethasone—multiple sclerosis	6.17e-05	0.000513	CcSEcCtD
Raltegravir—Hyperhidrosis—Betamethasone—multiple sclerosis	6.17e-05	0.000513	CcSEcCtD
Raltegravir—Malaise—Prednisone—multiple sclerosis	6.14e-05	0.000511	CcSEcCtD
Raltegravir—Vertigo—Prednisone—multiple sclerosis	6.12e-05	0.000509	CcSEcCtD
Raltegravir—Eye disorder—Methotrexate—multiple sclerosis	6.11e-05	0.000508	CcSEcCtD
Raltegravir—Tinnitus—Methotrexate—multiple sclerosis	6.09e-05	0.000507	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CD80—multiple sclerosis	6.09e-05	0.000974	CbGpPWpGaD
Raltegravir—Urticaria—Prednisolone—multiple sclerosis	6.07e-05	0.000505	CcSEcCtD
Raltegravir—Cardiac disorder—Methotrexate—multiple sclerosis	6.07e-05	0.000505	CcSEcCtD
Raltegravir—Fatigue—Triamcinolone—multiple sclerosis	6.06e-05	0.000504	CcSEcCtD
Raltegravir—Fatigue—Methylprednisolone—multiple sclerosis	6.05e-05	0.000503	CcSEcCtD
Raltegravir—Pain—Triamcinolone—multiple sclerosis	6.01e-05	0.0005	CcSEcCtD
Raltegravir—Angiopathy—Methotrexate—multiple sclerosis	5.93e-05	0.000493	CcSEcCtD
Raltegravir—Vomiting—Mitoxantrone—multiple sclerosis	5.93e-05	0.000493	CcSEcCtD
Raltegravir—Immune system disorder—Methotrexate—multiple sclerosis	5.9e-05	0.000491	CcSEcCtD
Raltegravir—Mediastinal disorder—Methotrexate—multiple sclerosis	5.89e-05	0.00049	CcSEcCtD
Raltegravir—Hypertension—Prednisone—multiple sclerosis	5.88e-05	0.000489	CcSEcCtD
Raltegravir—Rash—Mitoxantrone—multiple sclerosis	5.88e-05	0.000489	CcSEcCtD
Raltegravir—Dermatitis—Mitoxantrone—multiple sclerosis	5.87e-05	0.000489	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GPC5—multiple sclerosis	5.87e-05	0.000938	CbGpPWpGaD
Raltegravir—Chills—Methotrexate—multiple sclerosis	5.86e-05	0.000488	CcSEcCtD
Raltegravir—Headache—Mitoxantrone—multiple sclerosis	5.84e-05	0.000486	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.81e-05	0.000484	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.81e-05	0.000484	CcSEcCtD
Raltegravir—Arthralgia—Prednisone—multiple sclerosis	5.8e-05	0.000482	CcSEcCtD
Raltegravir—Myalgia—Prednisone—multiple sclerosis	5.8e-05	0.000482	CcSEcCtD
Raltegravir—Feeling abnormal—Triamcinolone—multiple sclerosis	5.79e-05	0.000482	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—POMC—multiple sclerosis	5.79e-05	0.000925	CbGpPWpGaD
Raltegravir—Feeling abnormal—Methylprednisolone—multiple sclerosis	5.78e-05	0.000481	CcSEcCtD
Raltegravir—Anxiety—Prednisone—multiple sclerosis	5.78e-05	0.000481	CcSEcCtD
Raltegravir—Alopecia—Methotrexate—multiple sclerosis	5.78e-05	0.000481	CcSEcCtD
Raltegravir—Insomnia—Betamethasone—multiple sclerosis	5.77e-05	0.00048	CcSEcCtD
Raltegravir—Insomnia—Dexamethasone—multiple sclerosis	5.77e-05	0.00048	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	5.76e-05	0.000479	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	5.74e-05	0.000477	CcSEcCtD
Raltegravir—Paraesthesia—Dexamethasone—multiple sclerosis	5.73e-05	0.000477	CcSEcCtD
Raltegravir—Paraesthesia—Betamethasone—multiple sclerosis	5.73e-05	0.000477	CcSEcCtD
Raltegravir—Discomfort—Prednisone—multiple sclerosis	5.73e-05	0.000477	CcSEcCtD
Raltegravir—Mental disorder—Methotrexate—multiple sclerosis	5.73e-05	0.000476	CcSEcCtD
Raltegravir—Erythema—Methotrexate—multiple sclerosis	5.69e-05	0.000473	CcSEcCtD
Raltegravir—Malnutrition—Methotrexate—multiple sclerosis	5.69e-05	0.000473	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCL2—multiple sclerosis	5.66e-05	0.000905	CbGpPWpGaD
Raltegravir—Hypersensitivity—Prednisolone—multiple sclerosis	5.63e-05	0.000469	CcSEcCtD
Raltegravir—Dyspepsia—Dexamethasone—multiple sclerosis	5.62e-05	0.000467	CcSEcCtD
Raltegravir—Dyspepsia—Betamethasone—multiple sclerosis	5.62e-05	0.000467	CcSEcCtD
Raltegravir—Urticaria—Triamcinolone—multiple sclerosis	5.59e-05	0.000465	CcSEcCtD
Raltegravir—Urticaria—Methylprednisolone—multiple sclerosis	5.57e-05	0.000464	CcSEcCtD
Raltegravir—Dysgeusia—Methotrexate—multiple sclerosis	5.57e-05	0.000464	CcSEcCtD
Raltegravir—Body temperature increased—Triamcinolone—multiple sclerosis	5.56e-05	0.000463	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—multiple sclerosis	5.55e-05	0.000887	CbGpPWpGaD
Raltegravir—Abdominal pain—Methylprednisolone—multiple sclerosis	5.55e-05	0.000462	CcSEcCtD
Raltegravir—Decreased appetite—Dexamethasone—multiple sclerosis	5.55e-05	0.000462	CcSEcCtD
Raltegravir—Decreased appetite—Betamethasone—multiple sclerosis	5.55e-05	0.000462	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—MAPK1—multiple sclerosis	5.54e-05	0.000885	CbGpPWpGaD
Raltegravir—Nausea—Mitoxantrone—multiple sclerosis	5.54e-05	0.000461	CcSEcCtD
Raltegravir—Infection—Prednisone—multiple sclerosis	5.52e-05	0.000459	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	5.51e-05	0.000458	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Betamethasone—multiple sclerosis	5.51e-05	0.000458	CcSEcCtD
Raltegravir—Back pain—Methotrexate—multiple sclerosis	5.5e-05	0.000458	CcSEcCtD
Raltegravir—Fatigue—Dexamethasone—multiple sclerosis	5.5e-05	0.000458	CcSEcCtD
Raltegravir—Fatigue—Betamethasone—multiple sclerosis	5.5e-05	0.000458	CcSEcCtD
Raltegravir—Pain—Dexamethasone—multiple sclerosis	5.46e-05	0.000454	CcSEcCtD
Raltegravir—Pain—Betamethasone—multiple sclerosis	5.46e-05	0.000454	CcSEcCtD
Raltegravir—Nervous system disorder—Prednisone—multiple sclerosis	5.45e-05	0.000453	CcSEcCtD
Raltegravir—Skin disorder—Prednisone—multiple sclerosis	5.4e-05	0.000449	CcSEcCtD
Raltegravir—Hyperhidrosis—Prednisone—multiple sclerosis	5.37e-05	0.000447	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—multiple sclerosis	5.28e-05	0.000439	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—multiple sclerosis	5.26e-05	0.000438	CcSEcCtD
Raltegravir—Feeling abnormal—Dexamethasone—multiple sclerosis	5.26e-05	0.000437	CcSEcCtD
Raltegravir—Feeling abnormal—Betamethasone—multiple sclerosis	5.26e-05	0.000437	CcSEcCtD
Raltegravir—Gastrointestinal pain—Betamethasone—multiple sclerosis	5.22e-05	0.000434	CcSEcCtD
Raltegravir—Gastrointestinal pain—Dexamethasone—multiple sclerosis	5.22e-05	0.000434	CcSEcCtD
Raltegravir—Hypersensitivity—Triamcinolone—multiple sclerosis	5.18e-05	0.000431	CcSEcCtD
Raltegravir—Hypersensitivity—Methylprednisolone—multiple sclerosis	5.17e-05	0.00043	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TYK2—multiple sclerosis	5.14e-05	0.000822	CbGpPWpGaD
Raltegravir—Malaise—Methotrexate—multiple sclerosis	5.13e-05	0.000427	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—multiple sclerosis	5.11e-05	0.000425	CcSEcCtD
Raltegravir—Urticaria—Dexamethasone—multiple sclerosis	5.07e-05	0.000422	CcSEcCtD
Raltegravir—Urticaria—Betamethasone—multiple sclerosis	5.07e-05	0.000422	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Prednisone—multiple sclerosis	5.06e-05	0.000421	CcSEcCtD
Raltegravir—Dizziness—Prednisolone—multiple sclerosis	5.06e-05	0.000421	CcSEcCtD
Raltegravir—Asthenia—Triamcinolone—multiple sclerosis	5.04e-05	0.00042	CcSEcCtD
Raltegravir—Body temperature increased—Betamethasone—multiple sclerosis	5.04e-05	0.00042	CcSEcCtD
Raltegravir—Abdominal pain—Betamethasone—multiple sclerosis	5.04e-05	0.00042	CcSEcCtD
Raltegravir—Body temperature increased—Dexamethasone—multiple sclerosis	5.04e-05	0.00042	CcSEcCtD
Raltegravir—Abdominal pain—Dexamethasone—multiple sclerosis	5.04e-05	0.00042	CcSEcCtD
Raltegravir—Asthenia—Methylprednisolone—multiple sclerosis	5.03e-05	0.000419	CcSEcCtD
Raltegravir—Insomnia—Prednisone—multiple sclerosis	5.03e-05	0.000418	CcSEcCtD
Raltegravir—Paraesthesia—Prednisone—multiple sclerosis	4.99e-05	0.000415	CcSEcCtD
Raltegravir—Pruritus—Triamcinolone—multiple sclerosis	4.97e-05	0.000414	CcSEcCtD
Raltegravir—Cough—Methotrexate—multiple sclerosis	4.96e-05	0.000413	CcSEcCtD
Raltegravir—Pruritus—Methylprednisolone—multiple sclerosis	4.96e-05	0.000413	CcSEcCtD
Raltegravir—Dyspepsia—Prednisone—multiple sclerosis	4.89e-05	0.000407	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—RRM1—multiple sclerosis	4.86e-05	0.000777	CbGpPWpGaD
Raltegravir—Chest pain—Methotrexate—multiple sclerosis	4.84e-05	0.000403	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—multiple sclerosis	4.84e-05	0.000403	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—multiple sclerosis	4.84e-05	0.000403	CcSEcCtD
Raltegravir—Decreased appetite—Prednisone—multiple sclerosis	4.83e-05	0.000402	CcSEcCtD
Raltegravir—Rash—Prednisolone—multiple sclerosis	4.82e-05	0.000401	CcSEcCtD
Raltegravir—Dermatitis—Prednisolone—multiple sclerosis	4.82e-05	0.000401	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	4.81e-05	0.0004	CcSEcCtD
Raltegravir—Diarrhoea—Methylprednisolone—multiple sclerosis	4.8e-05	0.000399	CcSEcCtD
Raltegravir—Fatigue—Prednisone—multiple sclerosis	4.79e-05	0.000399	CcSEcCtD
Raltegravir—Headache—Prednisolone—multiple sclerosis	4.79e-05	0.000399	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—multiple sclerosis	4.79e-05	0.000398	CcSEcCtD
Raltegravir—Constipation—Prednisone—multiple sclerosis	4.75e-05	0.000395	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—multiple sclerosis	4.68e-05	0.00039	CcSEcCtD
Raltegravir—Dizziness—Triamcinolone—multiple sclerosis	4.65e-05	0.000387	CcSEcCtD
Raltegravir—Dizziness—Methylprednisolone—multiple sclerosis	4.64e-05	0.000386	CcSEcCtD
Raltegravir—Infection—Methotrexate—multiple sclerosis	4.61e-05	0.000384	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisone—multiple sclerosis	4.58e-05	0.000381	CcSEcCtD
Raltegravir—Asthenia—Dexamethasone—multiple sclerosis	4.58e-05	0.000381	CcSEcCtD
Raltegravir—Asthenia—Betamethasone—multiple sclerosis	4.58e-05	0.000381	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—multiple sclerosis	4.55e-05	0.000379	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—multiple sclerosis	4.55e-05	0.000378	CcSEcCtD
Raltegravir—Gastrointestinal pain—Prednisone—multiple sclerosis	4.54e-05	0.000378	CcSEcCtD
Raltegravir—Nausea—Prednisolone—multiple sclerosis	4.54e-05	0.000378	CcSEcCtD
Raltegravir—Pruritus—Betamethasone—multiple sclerosis	4.51e-05	0.000376	CcSEcCtD
Raltegravir—Pruritus—Dexamethasone—multiple sclerosis	4.51e-05	0.000376	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—multiple sclerosis	4.51e-05	0.000375	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—multiple sclerosis	4.49e-05	0.000374	CcSEcCtD
Raltegravir—Vomiting—Triamcinolone—multiple sclerosis	4.47e-05	0.000372	CcSEcCtD
Raltegravir—Vomiting—Methylprednisolone—multiple sclerosis	4.46e-05	0.000371	CcSEcCtD
Raltegravir—Rash—Triamcinolone—multiple sclerosis	4.43e-05	0.000369	CcSEcCtD
Raltegravir—Dermatitis—Triamcinolone—multiple sclerosis	4.43e-05	0.000369	CcSEcCtD
Raltegravir—Rash—Methylprednisolone—multiple sclerosis	4.42e-05	0.000368	CcSEcCtD
Raltegravir—Dermatitis—Methylprednisolone—multiple sclerosis	4.42e-05	0.000368	CcSEcCtD
Raltegravir—Urticaria—Prednisone—multiple sclerosis	4.41e-05	0.000367	CcSEcCtD
Raltegravir—Headache—Triamcinolone—multiple sclerosis	4.4e-05	0.000367	CcSEcCtD
Raltegravir—Headache—Methylprednisolone—multiple sclerosis	4.4e-05	0.000366	CcSEcCtD
Raltegravir—Abdominal pain—Prednisone—multiple sclerosis	4.39e-05	0.000365	CcSEcCtD
Raltegravir—Body temperature increased—Prednisone—multiple sclerosis	4.39e-05	0.000365	CcSEcCtD
Raltegravir—Diarrhoea—Dexamethasone—multiple sclerosis	4.37e-05	0.000363	CcSEcCtD
Raltegravir—Diarrhoea—Betamethasone—multiple sclerosis	4.37e-05	0.000363	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL2—multiple sclerosis	4.28e-05	0.000684	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—multiple sclerosis	4.26e-05	0.00068	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.23e-05	0.000352	CcSEcCtD
Raltegravir—Dizziness—Dexamethasone—multiple sclerosis	4.22e-05	0.000351	CcSEcCtD
Raltegravir—Dizziness—Betamethasone—multiple sclerosis	4.22e-05	0.000351	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—multiple sclerosis	4.2e-05	0.000349	CcSEcCtD
Raltegravir—Nausea—Triamcinolone—multiple sclerosis	4.18e-05	0.000348	CcSEcCtD
Raltegravir—Paraesthesia—Methotrexate—multiple sclerosis	4.17e-05	0.000347	CcSEcCtD
Raltegravir—Nausea—Methylprednisolone—multiple sclerosis	4.17e-05	0.000347	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—multiple sclerosis	4.13e-05	0.000344	CcSEcCtD
Raltegravir—Hypersensitivity—Prednisone—multiple sclerosis	4.09e-05	0.000341	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—multiple sclerosis	4.09e-05	0.00034	CcSEcCtD
Raltegravir—Vomiting—Dexamethasone—multiple sclerosis	4.06e-05	0.000338	CcSEcCtD
Raltegravir—Vomiting—Betamethasone—multiple sclerosis	4.06e-05	0.000338	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—multiple sclerosis	4.05e-05	0.000647	CbGpPWpGaD
Raltegravir—Decreased appetite—Methotrexate—multiple sclerosis	4.04e-05	0.000336	CcSEcCtD
Raltegravir—Rash—Dexamethasone—multiple sclerosis	4.02e-05	0.000335	CcSEcCtD
Raltegravir—Rash—Betamethasone—multiple sclerosis	4.02e-05	0.000335	CcSEcCtD
Raltegravir—Dermatitis—Betamethasone—multiple sclerosis	4.02e-05	0.000334	CcSEcCtD
Raltegravir—Dermatitis—Dexamethasone—multiple sclerosis	4.02e-05	0.000334	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.01e-05	0.000334	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—multiple sclerosis	4e-05	0.000333	CcSEcCtD
Raltegravir—Headache—Dexamethasone—multiple sclerosis	4e-05	0.000333	CcSEcCtD
Raltegravir—Headache—Betamethasone—multiple sclerosis	4e-05	0.000333	CcSEcCtD
Raltegravir—Asthenia—Prednisone—multiple sclerosis	3.99e-05	0.000332	CcSEcCtD
Raltegravir—Pain—Methotrexate—multiple sclerosis	3.97e-05	0.00033	CcSEcCtD
Raltegravir—Pruritus—Prednisone—multiple sclerosis	3.93e-05	0.000327	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—multiple sclerosis	3.83e-05	0.000318	CcSEcCtD
Raltegravir—Diarrhoea—Prednisone—multiple sclerosis	3.8e-05	0.000316	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—multiple sclerosis	3.8e-05	0.000316	CcSEcCtD
Raltegravir—Nausea—Betamethasone—multiple sclerosis	3.79e-05	0.000315	CcSEcCtD
Raltegravir—Nausea—Dexamethasone—multiple sclerosis	3.79e-05	0.000315	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—multiple sclerosis	3.69e-05	0.000307	CcSEcCtD
Raltegravir—Dizziness—Prednisone—multiple sclerosis	3.67e-05	0.000306	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—multiple sclerosis	3.67e-05	0.000305	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—multiple sclerosis	3.67e-05	0.000305	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—STAT3—multiple sclerosis	3.6e-05	0.000575	CbGpPWpGaD
Raltegravir—Vomiting—Prednisone—multiple sclerosis	3.53e-05	0.000294	CcSEcCtD
Raltegravir—Rash—Prednisone—multiple sclerosis	3.5e-05	0.000292	CcSEcCtD
Raltegravir—Dermatitis—Prednisone—multiple sclerosis	3.5e-05	0.000291	CcSEcCtD
Raltegravir—Headache—Prednisone—multiple sclerosis	3.48e-05	0.00029	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—multiple sclerosis	3.42e-05	0.000285	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—multiple sclerosis	3.35e-05	0.000535	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—multiple sclerosis	3.34e-05	0.000533	CbGpPWpGaD
Raltegravir—Asthenia—Methotrexate—multiple sclerosis	3.33e-05	0.000277	CcSEcCtD
Raltegravir—Nausea—Prednisone—multiple sclerosis	3.3e-05	0.000275	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—multiple sclerosis	3.29e-05	0.000273	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MAPK1—multiple sclerosis	3.27e-05	0.000523	CbGpPWpGaD
Raltegravir—Diarrhoea—Methotrexate—multiple sclerosis	3.18e-05	0.000264	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—multiple sclerosis	3.07e-05	0.000256	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—multiple sclerosis	2.95e-05	0.000246	CcSEcCtD
Raltegravir—Rash—Methotrexate—multiple sclerosis	2.93e-05	0.000244	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—multiple sclerosis	2.93e-05	0.000243	CcSEcCtD
Raltegravir—Headache—Methotrexate—multiple sclerosis	2.91e-05	0.000242	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—BCHE—multiple sclerosis	2.79e-05	0.000446	CbGpPWpGaD
Raltegravir—Nausea—Methotrexate—multiple sclerosis	2.76e-05	0.00023	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—IL6—multiple sclerosis	2.51e-05	0.000402	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOE—multiple sclerosis	1.68e-05	0.000268	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—POMC—multiple sclerosis	1.44e-05	0.000231	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—multiple sclerosis	1.32e-05	0.00021	CbGpPWpGaD
